ArticleCureus2026
Cystic Fibrosis With No Known Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation and a Negative Newborn Screening Test: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) is a progressive, autosomal recessive disease primarily affecting the pulmonary and gastrointestinal systems of afflicted individuals. Cystic fibrosis transmembrane receptor (CFTR) genes encode the CFTR protein, which allows chloride ions to pass from inside the cell to the outside of the cell. CF symptoms, such as thick, sticky mucous, result from CFTR gene dysfunction. Although many mutations in the CFTR gene have been identified, there remains an absence of a comprehensive database encompassing all known and potential mutations contributing to the pathogenesis of CF. We present a 12-year-old male with recurrent sino-pulmonary infections, asthma exacerbations, and failure to thrive. Despite a negative newborn screening test, CF was suspected. The sweat chloride test is considered the gold standard for confirming CF. This patient's sweat chloride test showed elevated levels of 63 and 66 mmol/L, respectively. Levels >60 mmol/L are considered consistent with CF. CF genotyping, however, did not uncover a known CFTR mutation. The purpose of this case report is to highlight the importance of the sweat chloride test in diagnosing CF in the setting of a negative newborn screen and the absence of a known CFTR mutation, to enhance the diagnosis and recognition of CF in pediatric patients, and to ultimately improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.